Popular weight-loss drugs show promising new power against debilitating migraines
In a small study, a GLP-1 drug shrank the number of days people spent with a migraine by almost half in a given month.
Presented at the European Academy of Neurology Congress in Helinski, Finland, on June 21, the results suggest promising future uses of the popular obesity and diabetes drugs.
Who Should Be Taking Weight-loss Drugs? Doctors Share Best Candidates
Nearly 40 million Americans deal with migraines, according to the World Health Organization (WHO) — and for many, they're more than just a headache.
Migraines are the second-leading cause of disability worldwide, the above agency states, with symptoms including severe headaches, nausea and sensitivity to light often disrupting daily activities.
Read On The Fox News App
Previous studies have shown that GLP-1s can reduce pressure inside the skull, which is a possible cause of migraines, according to multiple health organizations.
Neurologist and study lead Simone Braca of the University of Naples Federico II in Italy, along with his colleagues, explored whether liraglutide, an earlier version of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), could help migraine sufferers.
Thirty-one adults, 26 of them women, got daily injections of liraglutide for 12 weeks. The participants, who all met the criteria for obesity, also continued to take their current migraine medications.
At the start of the experiment, participants reported headaches about 20 days out of a month. After 12 weeks of liraglutide, the average number dropped to about 11 days.
"Most patients felt better within the first two weeks and reported quality of life improved significantly," said Braca in a press release for the study, which was published in the journal Headache last month.
The relief from migraines lasted for the full three-month observation period, the researcher noted, although weight loss was "modest and statistically non-significant."
Participants' weight stayed about the same during the trial, suggesting that the headache reductions weren't tied to weight loss.
Weight-loss Medications May Also Benefit Common Medical Problem, Study Finds
"Liraglutide is a 'middle-aged' GLP-1, with Ozempic and Mounjaro being newer," Dr. Sue Decotiis, a triple board-certified weight loss specialist in New York City, told Fox News Digital.
Decotiis, who was not involved in the study, said that liraglutide is not as effective as its newer cousins for weight loss or diabetes, and is not frequently used for these purposes.
"Many pharmacies are not even stocking it due to declining demand, yet it gets into the brain well enough to reduce migraines," she noted.
The trial didn't include a comparison group, and participants and researchers all knew that everyone received liraglutide, the researchers noted.
Mild gastrointestinal side effects (mainly nausea and constipation) occurred in 38% of participants, but did not lead to treatment discontinuation.
Further research may include other groups, such as control groups and people without obesity, to compare the drug's effects.
"The study was very small," Decotiis confirmed to Fox News Digital.
Given its size and brief duration, the findings could be limited until further research is conducted, according to the expert.
Click Here To Sign Up For Our Health Newsletter
The researchers also tested only one drug, liraglutide, "which is not used as frequently in the general population as semaglutide or tirzepatide are," Decotiis added.
For more Health articles, visit www.foxnews.com/health
Next, the team is planning a randomized, double-blind trial that will also measure pressure inside the skull.
"We also want to determine whether other GLP-1 drugs can deliver the same relief, possibly with even fewer gastrointestinal side effects," Braca said in the same press release.Original article source: Popular weight-loss drugs show promising new power against debilitating migraines
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Medimaps launches AI-image software for osteoporosis in Europe
Switzerland-based Medimaps has launched a new version of its artificial intelligence (AI)-based image processing software for osteoporosis assessment in Europe. Trabecular Bone Score (TBS) Osteo Advanced uses AI to correct for soft tissue thickness anterior to the lumbar spine to ensure greater TBS assessment accuracy across a wide range of body types. This latest software builds on the original TBS Osteo, which was first introduced in 2012. The new version can be centrally managed through healthcare organisations' Dual-energy X-ray (DXA) scanners for bone density assessment, with workflows standardised across multiple locations. TBS Osteo Advanced is available under a subscription model, allowing healthcare organisations to keep up to date with the latest developments in osteoporosis care. The European launch follows its certification under the EU's Medical Device Regulation (EU MDR) in January 2025. The software received 510(k) clearance from the US Food and Drug Administration (FDA) in the same month and launched across the US in June. According to Medimaps, since the US launch in 2012, TBS Osteo has been adopted by 16 of the country's top 20 hospitals and healthcare providers. Medimaps CEO Dr Didier Hans said the updated version of TBS Osteo has been developed to provide radiologists with a maximum of clinical output with a minimum of logistics. 'Designed for seamless integration into clinical workflows, it requires no additional exam time or extra appointments – an essential advantage for busy radiology professionals,' Hans said. 'TBS Osteo delivers within seconds a comprehensive report combining bone mineral density (BMD) and clinical factors, providing results beyond the standard of care.' Medimaps' TBS Osteo Advanced is built on its TBS iNsight engine which received EU MDR certification in 2023. Osteoporosis weakens bones and increases the risk of bone fractures. According to the International Osteoporosis Foundation, around 32 million Europeans aged 50 and above live with the condition. Across the EU, Switzerland, and the UK, osteoporotic fractures are projected to rise to 5.3 million annually by 2034, up from 4.9 million in 2019. Research by the United Nations (UN) projects that the global population aged 60 and above will reach around 2.1 billion by 2050. According to GlobalData analysis, the ageing population is set to have a profound influence on the medical device industry, with early detection and diagnosis of age-related diseases viewed as a critical determinate in improving health outcomes. "Medimaps launches AI-image software for osteoporosis in Europe" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Modella AI and AstraZeneca link for cancer clinical development
Modella AI has signed a multi-year agreement with AstraZeneca to expedite AI-driven oncology clinical development. The partnership will give AstraZeneca access to Modella AI's multi-modal foundation models. The agreement will enable the use of Modella AI's latest models, with rich feature extraction from different types of data, to speed up clinical development across AstraZeneca's worldwide oncology portfolio. AstraZeneca oncology research and development (R&D) chief AI and data scientist Jorge Reis-Filho stated: 'At AstraZeneca, AI is integrated across every aspect of clinical development. 'Through the use of foundation models, combined with our unique datasets and AI expertise, we are confident in our strategy to accelerate development and increase the probabilities of success in our oncology clinical trials.' AstraZeneca will use Modella AI's platform for cancer research R&D capabilities to improve biomarker discovery and clinical development while enhancing patient outcomes. By integrating these advanced foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods with increased speed. Modella AI CEO Jill Stefanelli stated: 'Foundation models are transforming precision medicine. They are the backbone of AI-powered biomedical discovery and mark the first step toward fully autonomous AI agents. 'Our state-of-the-art multimodal foundation models provide powerful features from different data types for downstream tasks. When integrated with AstraZeneca's research engine, they will have the potential to accelerate data-driven development and enable the development of new AI agents that can automate complex R&D workflows.' In June 2025, the US Food and Drug Administration (FDA) approved AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that exhibits mutations in the epidermal growth factor receptor. "Modella AI and AstraZeneca link for cancer clinical development" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
AstraZeneca's Imfinzi approved in Europe for muscle-invasive bladder cancer
AstraZeneca has added another indication to its blockbuster immunotherapy Imfinzi (durvalumab), gaining European approval to treat a type of bladder cancer. Imfinzi is now approved to treat adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with chemotherapy drugs gemcitabine and cisplatin as neoadjuvant treatment, and as a monotherapy after bladder removal surgery. The approval comes as reports circulate that AstraZeneca CEO Pascal Soriot is considering delisting the company from the London Stock Exchange in favour of a US listing. Although no official decision has been announced, the prospect of such a move has sparked significant concern, given that AstraZeneca is currently the most valuable company in the UK. The pharmaceutical giant is said to be increasingly frustrated with growing regulatory pressures in the UK. Tensions escalated in late January when the company scrapped a £450m plan to turn its Speke-based facility into a major vaccine hub, after failing to reach an agreement with government ministers over the level of state support. Data from the Phase III NIAGARA (NCT03732677) trial demonstrated a 32% reduction in the risk of disease progression, recurrence, not undergoing surgery, or death, when compared to surgery alone. Around 67.8% of patients treated with AstraZeneca's drug were event-free at two years compared to 59.8% in the comparator arm. Bladder cancer is the ninth most common cancer in the world, with more than 614,000 patients diagnosed each year. Bladder cancer is considered muscle-invasive when there is evidence of the tumour invading the muscle wall of the bladder but no distant metastases. Of those who undergo bladder removal surgery, 50% experience disease recurrence. Imfinzi garnered attention when the data showcased a reduction in the risk of death by 25%, making it the first PD-1/L1 inhibitor to achieve a feat for MIBC patients. Imfinzi side effects were in line with expectations and did not compromise patients' ability to complete surgery compared to neoadjuvant chemotherapy alone. The European approval follows a similar decision made by the US Food and Drug Administration (FDA) in March 2025. Imfinzi is a major revenue driver for AstraZeneca, generating around $4.7bn in sales in 2024. Its European label covers a range of cancers, including lung, biliary tract, and liver, amongst others. With entry to the market, Imfinzi stands alone as the only perioperative immunotherapy for muscle-invasive bladder cancer. GlobalData's Pharma Intelligence Center forecasts global sales for the drug to peak in 2030, generating $7bn in revenue. AstraZeneca is also eying up label expansions for Imfinzi in non-muscle invasive bladder cancer (NMIBC), a larger market given that 70% of new bladder cancer diagnoses come from this segment. Imfinzi has already demonstrated positive results for this indication in the Phase III POTOMAC trial (NCT03528694). MSD's Keytruda (pembrolizumab) – the bestselling drug in the world – dominates NMIBC, though Pfizer also has a strong PD-1 candidate in a Phase III trial. "AstraZeneca's Imfinzi approved in Europe for muscle-invasive bladder cancer" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
